Reversing the Warburg Effect as a Treatment for Glioblastoma

Stupp, 2002, Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide, J. Clin. Oncol., 20, 1375, 10.1200/JCO.2002.20.5.1375 Oertel, 2005, Prognosis of gliomas in the 1970s and today, Neurosurg. Focus, 18, e12, 10.3171/foc.2005.18.4.13 Lacroix, 2001, A multivariate analysis of 416 patients with glioblastoma multiforme. Prognosis, extent of resection, and survival, J. Neurosurg., 95, 190, 10.3171/jns.2001.95.2.0190 Chamberlain, 2007, Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma, J. Neurooncol, 82, 81, 10.1007/s11060-006-9241-y Birol Sarica, 2010, Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme. Multivariate analysis and other prognostic factors, J. Neurosurg. Sci., 54, 7 Nieder, 2006, Combined modality treatment of glioblastoma multiforme. The role of temozolomide, Rev. Recent Clin. Trials, 1, 43, 10.2174/157488706775246148 Warburg, 1956, On the origin of cancer cells, Science, 123, 309, 10.1126/science.123.3191.309 Koppenol, 2011, Otto Warburg's contributions to current concepts of cancer metabolism, Nat. Rev. Cancer, 11, 325, 10.1038/nrc3038 Vander Heiden, 2009, Understanding the Warburg effect. The metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809 Ohlow, 2011, Phenothiazine: the seven lives of pharmacology's first lead structure, Drug Discov, Today, 16, 119, 10.1016/j.drudis.2011.01.001 Rojas, 2012, Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue, Prog. Neurobiol., 96, 32, 10.1016/j.pneurobio.2011.10.007 Wen, 2011, Alternative mitochondrial electron transfer as a novel strategy for neuroprotection, J. Biol. Chem., 286, 16504, 10.1074/jbc.M110.208447 Atamna, 2008, Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways, FASEB J., 22, 703, 10.1096/fj.07-9610com Callaway, 2002, Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats, Neurosci. Lett., 332, 83, 10.1016/S0304-3940(02)00827-3 Sontag, 2012, Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models, J. Neurosci., 32, 11109, 10.1523/JNEUROSCI.0895-12.2012 Medina, 2011, Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity, Brain Pathol., 21, 140, 10.1111/j.1750-3639.2010.00430.x Weinstein, 1964, The Action of gramicidin D on isolated liver mitochondria, J. Biol. Chem., 239, 3031, 10.1016/S0021-9258(18)93848-2 Fields, 2011, CCAAT/enhancer binding protein β expression is increased in the brain during HIV-1-infection and contributes to regulation of astrocyte tissue inhibitor of metalloproteinase-1, J. Neurochem., 118, 93, 10.1111/j.1471-4159.2011.07203.x Cao, 2009, Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity, EMBO J., 28, 1505, 10.1038/emboj.2009.101 Friedman, 1988, Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents, Cancer Res., 48, 4189 Gehan, 1965, A generalized Wilcoxon test for comparing arbitrarily singly-censored samples, Biometrika, 52, 203, 10.1093/biomet/52.1-2.203 Jeon, 2012, AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress, Nature, 485, 661, 10.1038/nature11066 Diaz-Ruiz, 2011, The Warburg and Crabtree effects. On the origin of cancer cell energy metabolism and of yeast glucose repression, Biochim. Biophys. Acta, 1807, 568, 10.1016/j.bbabio.2010.08.010 Schulz, 2006, Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth. Otto Warburg revisited, J. Biol. Chem., 281, 977, 10.1074/jbc.M511064200 DeBerardinis, 2008, The biology of cancer. Metabolic reprogramming fuels cell growth and proliferation, Cell metab., 7, 11, 10.1016/j.cmet.2007.10.002 Jones, 2009, Tumor suppressors and cell metabolism. A recipe for cancer growth, Genes Dev., 23, 537, 10.1101/gad.1756509 McCarty, 2010, Manipulating tumor acidification as a cancer treatment strategy, Altern. Med. Rev., 15, 264 Pagano, 1992, Cyclin A is required at two points in the human cell cycle, EMBO J., 11, 961, 10.1002/j.1460-2075.1992.tb05135.x Lindqvist, 2009, The decision to enter mitosis. Feedback and redundancy in the mitotic entry network, J. Cell Biol., 185, 193, 10.1083/jcb.200812045 Lauper, 1998, Cyclin E2. A novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle, Oncogene, 17, 2637, 10.1038/sj.onc.1202477 Carling, 2004, The AMP-activated protein kinase cascade. A unifying system for energy control, Trends Biochem. Sci., 29, 18, 10.1016/j.tibs.2003.11.005 Bolster, 2002, AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling, J. Biol. Chem., 277, 23977, 10.1074/jbc.C200171200 Imamura, 2001, Cell cycle regulation via p53 phosphorylation by a 5‘-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside, in a human hepatocellular carcinoma cell line, Biochem. Biophys. Res. Commun., 287, 562, 10.1006/bbrc.2001.5627 Hawley, 2003, Complexes between the LKB1 tumor suppressor, STRAD α/β, and MO25 α/β are upstream kinases in the AMP-activated protein kinase cascade, J. Biol., 2, 28, 10.1186/1475-4924-2-28 Jensen, 2007, Possible CaMKK-dependent regulation of AMPK phosphorylation and glucose uptake at the onset of mild tetanic skeletal muscle contraction, Am. J. Physiol. Endocrinol. Metab., 292, E1308, 10.1152/ajpendo.00456.2006 Luo, 2010, AMPK as a metabolic tumor suppressor. Control of metabolism and cell growth, Future Oncol, 6, 457, 10.2217/fon.09.174 Rattan, 2011, Metformin attenuates ovarian cancer cell growth in an AMP kinase-dispensable manner, J. Cell. Mol. Med., 15, 166, 10.1111/j.1582-4934.2009.00954.x Xiang, 2004, AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms, Biochem. Biophys. Res. Commun., 321, 161, 10.1016/j.bbrc.2004.06.133 Youn, 2012, Anticancer properties of pomolic acid-induced AMP-activated protein kinase activation in MCF7 human breast cancer cells, Biol. Pharm. Bull, 35, 105, 10.1248/bpb.35.105 Zhou, 2009, Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells, Oncogene, 28, 1993, 10.1038/onc.2009.63 Wu, 2011, Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153, Neoplasma, 58, 482, 10.4149/neo_2011_06_482 Wang, 2002, AMP-activated kinase regulates cytoplasmic HuR, Mol. Cell. Biol., 22, 3425, 10.1128/MCB.22.10.3425-3436.2002 Wakil, 1983, Fatty acid synthesis and its regulation, Annu. Rev. Biochem., 52, 537, 10.1146/annurev.bi.52.070183.002541 Park, 2002, Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle, J. Appl. Physiol., 92, 2475, 10.1152/japplphysiol.00071.2002 Chung, 1992, Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70-kDa S6 protein kinases, Cell, 69, 1227, 10.1016/0092-8674(92)90643-Q Price, 1992, Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase, Science, 257, 973, 10.1126/science.1380182 Hara, 2002, Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action, Cell, 110, 177, 10.1016/S0092-8674(02)00833-4 Sarbassov, 2005, Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex, Science, 307, 1098, 10.1126/science.1106148 Zakikhani, 2010, Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells, Breast Cancer Res. Treat, 123, 271, 10.1007/s10549-010-0763-9 Emerling, 2009, Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio, Free Radic. Biol. Med., 46, 1386, 10.1016/j.freeradbiomed.2009.02.019 Pepponi, 2003, The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin, J. Pharmacol. Exp. Ther., 304, 661, 10.1124/jpet.102.043950